ECBio´s work in straight collaboration with AIDFM/FMUL, shows for the first time that UCX® can stimulate angiogenesis and arteriogenesis, and thereby improve blood perfusion in the ischemic limbin of experimentally induced hind limb ischemia in vivo. These results suggest that UCX® could have clinical use in the treatment of lower limb vascular insufficiency. The results have been submitted for publication and have settled the grounds for ECBio’s PAD clinical programme.See more details under ClinUCX R&D results.